Table 2.
Parameter | T0–T1 | T1–T2 | T0–T2 | |
---|---|---|---|---|
ΔFMA-T | Cerebrolysin | 11.0 ± 11.8 | 12.3 ± 13.4 * | 23.3 ± 15.9 |
Placebo | 13.8 ± 15.2 | 6.7 ± 10.5 | 20.5 ± 18.8 | |
ΔFMA-UL | Cerebrolysin | 7.6 ± 8.7 | 8.2 ± 9.3 * | 15.8 ± 12.6 |
Placebo | 8.2 ± 11.0 | 4.4 ± 8.1 | 12.5 ± 13.3 | |
ΔFMA-LL | Cerebrolysin | 3.3 ± 5.0 | 4.0 ± 6.0 | 7.4 ± 6.3 |
Placebo | 5.6 ± 6.0 | 2.4 ± 4.8 | 8.0 ± 7.2 |
Values are means ± SDs; FMA-T, total Fugl–Meyer Assessment; FMA-UL, upper limb of FMA; FMA-LL, lower limb of FMA; * p < 0.05 compared with the placebo group.